{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:55:21Z","timestamp":1780466121197,"version":"3.54.1"},"reference-count":48,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UZ Brussel Foundation"},{"DOI":"10.13039\/501100006282","name":"King Baudouin Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["1SE9324N"],"award-info":[{"award-number":["1SE9324N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Minimal residual disease (MRD) persists in most multiple myeloma (MM) patients, causing relapse despite deep remissions. Repeatability of MRD detection in MM bone marrow (BM) samples is limited, underscoring the need for blood-based monitoring approaches that can allow more thorough disease surveillance. Methods: This study compares tumor detection rates in BM-derived DNA with different blood-derived DNA sources, using next-generation sequencing of the immunoglobulin locus (NGS-IG). CD138-targeted immunomagnetic enrichment of circulating tumor cells (CTCs) followed by vacuum evaporation to concentrate DNA was used to optimize the tumor detection rate. Results: Tumor DNA was detected in 76%, 88% and 100% of cell-free DNA, peripheral blood-derived mononuclear cells, DNA and enriched CTC-DNA samples of patients with active myeloma, respectively. These data indicate that enriched CTC samples were the most informative for evaluation of disease detection with NGS-IG in patients with active myeloma. MRD detection was performed in paired BM and enriched CTC-DNA samples from 37 patients in remission. MRD positivity was found in the BM of 24 patients, with half of them (12\/24) also showing the presence of MRD when enriched CTC-DNA was used. Interestingly, time to progression (TTP) of enriched CTC MRD-negative\/BM MRD-positive patients was comparable to that of double MRD-negative (BM and CTC) patients. Moreover, double positive patients showed a trend to earlier relapses. Conclusions: Our data suggest that NGS-IG analysis with enriched CTC-DNA may offer improved predictive abilities for relapse in multiple myeloma compared to the currently used BM-DNA-based tumor detection method.<\/jats:p>","DOI":"10.3390\/cancers17244008","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:47:26Z","timestamp":1765889246000},"page":"4008","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Analysis of Bone Marrow, cfDNA and CTCs for NGS-Based Multiple Myeloma Detection: A Pilot Study Indicating the Potential of CTCs"],"prefix":"10.3390","volume":"17","author":[{"given":"Wouter","family":"De Brouwer","sequence":"first","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-1705","authenticated-orcid":false,"given":"Robbe","family":"Heestermans","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Clinical Biology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0611-0687","authenticated-orcid":false,"given":"Jona","family":"Van der Straeten","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Clinical Biology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara","family":"Falise","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8708","authenticated-orcid":false,"given":"Ann","family":"De Becker","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7923-7149","authenticated-orcid":false,"given":"Isabelle","family":"Vande Broek","sequence":"additional","affiliation":[{"name":"Department of Hematology, VITAZ, Moerlandstraat 1, 9100 Sint-Niklaas, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Schots","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-3369","authenticated-orcid":false,"given":"Marleen","family":"Bakkus","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Clinical Biology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-4347","authenticated-orcid":false,"given":"Ivan","family":"Van Riet","sequence":"additional","affiliation":[{"name":"Research Group Hematology-Immunology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"},{"name":"Department of Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: How to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-020-01897-9","article-title":"Liquid biopsies for multiple myeloma in a time of precision medicine","volume":"98","author":"Ferreira","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations","volume":"194","author":"Beksac","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_8","unstructured":"National Library of Medicine (2022, June 08). Liquid Biopsy, Available online: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/?term=liquid+biopsy."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples","volume":"39","author":"Russano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2022, June 22). Cobas EGFR Mutation Test v2, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/cobas-egfr-mutation-test-v2."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2022, June 22). PMA P200010\/S010: FDA Summary of Safety and Effectiveness Data, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200010S010B.pdf."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2022, June 22). FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers and Biomarkers, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers."},{"key":"ref_13","first-page":"295","article-title":"Circulating tumor cells: A review of present methods and the need to identify heterogeneous phenotypes","volume":"43","author":"Millner","year":"2013","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1038\/s41375-021-01339-6","article-title":"Liquid biopsy: An evolving paradigm for the biological characterisation of plasma cell disorders","volume":"35","author":"Mithraprabhu","year":"2021","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Paiva","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1039\/C7IB00183E","article-title":"Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics","volume":"10","author":"Kamande","year":"2018","journal-title":"Integr. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/bmt.2017.91","article-title":"Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial","volume":"52","author":"Huhn","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Moser-Katz, T., Joseph, N.S., Dhodapkar, M.V., Lee, K.P., and Boise, L.H. (2021). Game of Bones: How Myeloma Manipulates Its Microenvironment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.625199"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lopes, R., Caetano, J., Ferreira, B., Barahona, F., Carneiro, E.A., and Jo\u00e3o, C. (2021). The Immune Microenvironment in Multiple Myeloma: Friend or Foe?. Cancers, 13.","DOI":"10.3390\/cancers13040625"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: Implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/bjh.13067","article-title":"Quantification of clonal circulating plasma cells in relapsed multiple myeloma","volume":"167","author":"Gonsalves","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, J., Wang, N., Tesfaluul, N., Gao, X., Liu, S., and Yue, B. (2017). Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181447"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bbmt.2013.04.025","article-title":"Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma","volume":"19","author":"Korthals","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/10428194.2021.1992765","article-title":"Significance of analyzing circulating plasma cells in multiple myeloma: Differences from measuring minimal residual diseases in bone marrow","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jmoldx.2018.07.006","article-title":"Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study","volume":"20","author":"Biancon","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.13358","article-title":"Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients","volume":"104","author":"Vrabel","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ejh.13541","article-title":"Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA","volume":"106","author":"Deshpande","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3324\/haematol.2013.093500","article-title":"Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Kubiczkova","year":"2014","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.18632\/oncotarget.2761","article-title":"A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma","volume":"6","author":"Navarro","year":"2015","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V73.4.1020.1020","article-title":"The human myeloma cell line LP-1: A versatile model in which to study early plasma-cell differentiation and c-myc activation","volume":"73","author":"Pegoraro","year":"1989","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jmoldx.2021.01.009","article-title":"Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators","volume":"23","author":"Kabongo","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_39","first-page":"604","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data","volume":"5","author":"Cazzaniga","year":"2007","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00277-019-03833-5","article-title":"Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma","volume":"98","author":"Wang","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.13927","article-title":"A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma","volume":"173","author":"Muz","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2014.321","article-title":"Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ab.2018.10.020","article-title":"Does vacuum centrifugal concentration reduce yield or quality of nucleic acids extracted from FFPE biospecimens?","volume":"566","author":"Betsou","year":"2019","journal-title":"Anal. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating Tumor Cells for the Staging of Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Cedena","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Heestermans, R., De Brouwer, W., Maes, K., Broek, I.V., Vaeyens, F., Olsen, C., Caljon, B., De Becker, A., Bakkus, M., and Schots, R. (2022). Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study. Cancers, 14.","DOI":"10.3390\/cancers14194901"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:30:52Z","timestamp":1766035852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/4008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":48,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17244008"],"URL":"https:\/\/doi.org\/10.3390\/cancers17244008","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}